FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4292681844> ?p ?o ?g. }

• W4292681844 abstract "Abstract Background The use of respiratory devices can mitigate the spread of diseases such as COVID-19 in community settings. We aimed to determine the effectiveness of closed face shields with surgical face masks to prevent SARS-CoV-2 transmission in working adults during the COVID-19 pandemic in Bogotá, Colombia. Methods An open-label non-inferiority randomized controlled trial that randomly assigned participants to one of two groups: the intervention group was instructed to wear closed face shields with surgical face masks, and the active control group was instructed to wear only surgical face masks. The primary outcome was a positive reverse transcription polymerase chain reaction test, IgG/IgM antibody test for SARS-CoV-2 detection, or both during and at the end of the follow-up period of 21 days. The non-inferiority limit was established at − 5%. Results A total of 316 participants were randomized, 160 participants were assigned to the intervention group and 156 to the active control group. In total, 141 (88.1%) participants in the intervention group and 142 (91.0%) in the active control group completed the follow-up. Primary outcome: a positive SARS-CoV-2 test result was identified in one (0.71%) participant in the intervention group and three (2.1%) in the active control group. In the intention-to-treat analysis, the absolute risk difference was − 1.40% (95% CI [− 4.14%, 1.33%]), and in the per-protocol analysis, the risk difference was − 1.40% (95% CI [− 4.20, 1.40]), indicating non-inferiority of the closed face shield plus face mask (did not cross the non-inferiority limit). Conclusions The use of closed face shields and surgical face masks was non-inferior to the surgical face mask alone in the prevention of SARS-CoV-2 infection in highly exposed groups. Settings with highly active viral transmission and conditions such as poor ventilation, crowding, and high mobility due to occupation may benefit from the combined use of masks and closed face shields to mitigate SARS-CoV-2 transmission. Trial registration ClinicalTrials.gov NCT04647305 . Registered on November 30, 2020" @default.
• W4292681844 created "2022-08-23" @default.
• W4292681844 creator A5006954935 @default.
• W4292681844 creator A5008491530 @default.
• W4292681844 creator A5011688907 @default.
• W4292681844 creator A5012406663 @default.
• W4292681844 creator A5019657757 @default.
• W4292681844 creator A5023223416 @default.
• W4292681844 creator A5026234327 @default.
• W4292681844 creator A5031629470 @default.
• W4292681844 creator A5043413884 @default.
• W4292681844 creator A5046033667 @default.
• W4292681844 creator A5048711169 @default.
• W4292681844 creator A5051860438 @default.
• W4292681844 creator A5053481185 @default.
• W4292681844 creator A5055916585 @default.
• W4292681844 creator A5057371180 @default.
• W4292681844 creator A5063543169 @default.
• W4292681844 creator A5065984237 @default.
• W4292681844 creator A5066003267 @default.
• W4292681844 creator A5069049830 @default.
• W4292681844 creator A5069249574 @default.
• W4292681844 creator A5071647777 @default.
• W4292681844 creator A5072185181 @default.
• W4292681844 creator A5072343080 @default.
• W4292681844 creator A5073495170 @default.
• W4292681844 creator A5073498858 @default.
• W4292681844 creator A5081244889 @default.
• W4292681844 date "2022-08-20" @default.
• W4292681844 modified "2023-10-17" @default.
• W4292681844 title "Effectiveness and adherence to closed face shields in the prevention of COVID-19 transmission: a non-inferiority randomized controlled trial in a middle-income setting (COVPROSHIELD)" @default.
• W4292681844 cites W1534533078 @default.
• W4292681844 cites W1910874260 @default.
• W4292681844 cites W2044998594 @default.
• W4292681844 cites W2282634950 @default.
• W4292681844 cites W3003739945 @default.
• W4292681844 cites W3008086759 @default.
• W4292681844 cites W3008443627 @default.
• W4292681844 cites W3010149441 @default.
• W4292681844 cites W3015790769 @default.
• W4292681844 cites W3019457420 @default.
• W4292681844 cites W3029343724 @default.
• W4292681844 cites W3030297573 @default.
• W4292681844 cites W3031867356 @default.
• W4292681844 cites W3032742287 @default.
• W4292681844 cites W3035180814 @default.
• W4292681844 cites W3035860952 @default.
• W4292681844 cites W3043891315 @default.
• W4292681844 cites W3044159317 @default.
• W4292681844 cites W3047052686 @default.
• W4292681844 cites W3048140877 @default.
• W4292681844 cites W3049615837 @default.
• W4292681844 cites W3081977846 @default.
• W4292681844 cites W3085155277 @default.
• W4292681844 cites W3099589848 @default.
• W4292681844 cites W3101490008 @default.
• W4292681844 cites W3111715005 @default.
• W4292681844 cites W3129699241 @default.
• W4292681844 cites W3165260738 @default.
• W4292681844 cites W3167695358 @default.
• W4292681844 cites W4231113527 @default.
• W4292681844 doi "https://doi.org/10.1186/s13063-022-06606-0" @default.
• W4292681844 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35987694" @default.
• W4292681844 hasPublicationYear "2022" @default.
• W4292681844 type Work @default.
• W4292681844 citedByCount "3" @default.
• W4292681844 countsByYear W42926818442023 @default.
• W4292681844 crossrefType "journal-article" @default.
• W4292681844 hasAuthorship W4292681844A5006954935 @default.
• W4292681844 hasAuthorship W4292681844A5008491530 @default.
• W4292681844 hasAuthorship W4292681844A5011688907 @default.
• W4292681844 hasAuthorship W4292681844A5012406663 @default.
• W4292681844 hasAuthorship W4292681844A5019657757 @default.
• W4292681844 hasAuthorship W4292681844A5023223416 @default.
• W4292681844 hasAuthorship W4292681844A5026234327 @default.
• W4292681844 hasAuthorship W4292681844A5031629470 @default.
• W4292681844 hasAuthorship W4292681844A5043413884 @default.
• W4292681844 hasAuthorship W4292681844A5046033667 @default.
• W4292681844 hasAuthorship W4292681844A5048711169 @default.
• W4292681844 hasAuthorship W4292681844A5051860438 @default.
• W4292681844 hasAuthorship W4292681844A5053481185 @default.
• W4292681844 hasAuthorship W4292681844A5055916585 @default.
• W4292681844 hasAuthorship W4292681844A5057371180 @default.
• W4292681844 hasAuthorship W4292681844A5063543169 @default.
• W4292681844 hasAuthorship W4292681844A5065984237 @default.
• W4292681844 hasAuthorship W4292681844A5066003267 @default.
• W4292681844 hasAuthorship W4292681844A5069049830 @default.
• W4292681844 hasAuthorship W4292681844A5069249574 @default.
• W4292681844 hasAuthorship W4292681844A5071647777 @default.
• W4292681844 hasAuthorship W4292681844A5072185181 @default.
• W4292681844 hasAuthorship W4292681844A5072343080 @default.
• W4292681844 hasAuthorship W4292681844A5073495170 @default.
• W4292681844 hasAuthorship W4292681844A5073498858 @default.
• W4292681844 hasAuthorship W4292681844A5081244889 @default.
• W4292681844 hasBestOaLocation W42926818441 @default.
• W4292681844 hasConcept C126322002 @default.
• W4292681844 hasConcept C141071460 @default.
• W4292681844 hasConcept C159110408 @default.
• W4292681844 hasConcept C160735492 @default.
• W4292681844 hasConcept C162324750 @default.

• next